KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Minority Interest: 2009-2020

Historic Minority Interest for Ionis Pharmaceuticals (IONS) over the last 3 years, with Sep 2020 value amounting to $223.2 million.

  • Ionis Pharmaceuticals' Minority Interest rose 38.08% to $223.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $223.2 million, marking a year-over-year increase of 38.08%. This contributed to the annual value of $213.5 million for FY2019, which is 53.47% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Minority Interest stood at $223.2 million for Q3 2020, which was up 2.58% from $217.6 million recorded in Q2 2020.
  • Over the past 5 years, Ionis Pharmaceuticals' Minority Interest peaked at $223.2 million during Q3 2020, and registered a low of $84.3 million during Q4 2017.
  • Moreover, its 3-year median value for Minority Interest was $179.8 million (2019), whereas its average is $169.9 million.
  • Data for Ionis Pharmaceuticals' Minority Interest shows a peak YoY skyrocketed of 109.74% (in 2019) over the last 5 years.
  • Ionis Pharmaceuticals' Minority Interest (Quarterly) stood at $84.3 million in 2017, then surged by 65.05% to $139.1 million in 2018, then spiked by 53.47% to $213.5 million in 2019, then skyrocketed by 38.08% to $223.2 million in 2020.
  • Its last three reported values are $223.2 million in Q3 2020, $217.6 million for Q2 2020, and $210.2 million during Q1 2020.